Literature DB >> 11755527

The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis.

Lianghua Bin1, Xiaoyan Li, Liang-Guo Xu, Hong-Bing Shu.   

Abstract

TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a member of the tumor necrosis factor family that selectively induces apoptosis of cancer cells. However, some cancer cells or subpopulations within cancer cell lines are resistant to TRAIL-induced apoptosis. We developed a retroviral cDNA library-based functional cloning approach to unambiguously identify putative inhibitory genes of TRAIL-induced apoptosis. This effort identified the short splice form of Casper/c-FLIP, Casper-S/c-FLIPs, as a major cellular protein that confers resistance to TRAIL-induced apoptosis. Furthermore, we found that Casper deficient embryonic fibroblasts (EFs) were highly sensitive while their wild-type counterparts were completely resistant to TRAIL-induced apoptosis. Retroviral-mediated transduction of Casper-S/c-FLIPs into Casper(-/-) EFs restored resistance to TRAIL. These data suggest that Casper-S/c-FLIPs is a major cellular inhibitor of TRAIL-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11755527     DOI: 10.1016/s0014-5793(01)03222-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

1.  mTOR-independent translational control of the extrinsic cell death pathway by RalA.

Authors:  Amith Panner; Jean L Nakamura; Andrew T Parsa; Pablo Rodriguez-Viciana; Mitchel S Berger; David Stokoe; Russell O Pieper
Journal:  Mol Cell Biol       Date:  2006-08-07       Impact factor: 4.272

2.  The nuclear splicing factor RNA binding motif 5 promotes caspase activation in human neuronal cells, and increases after traumatic brain injury in mice.

Authors:  Travis C Jackson; Lina Du; Keri Janesko-Feldman; Vincent A Vagni; Cameron Dezfulian; Samuel M Poloyac; Edwin K Jackson; Robert S B Clark; Patrick M Kochanek
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

3.  Effector CD4+ T cells generate intermediate caspase activity and cleavage of caspase-8 substrates.

Authors:  Ravi S Misra; Dawn M Jelley-Gibbs; Jennifer Q Russell; Gail Huston; Susan L Swain; Ralph C Budd
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

4.  mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells.

Authors:  Amith Panner; C David James; Mitchel S Berger; Russell O Pieper
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

5.  LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway.

Authors:  Jie Liu; Xue-Qiong Fu; Wei Zhou; Hong-Gang Yu; Jie-Ping Yu; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

6.  Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

Authors:  Tai-Guang Jin; Alexei Kurakin; Nordine Benhaga; Karon Abe; Mehrdad Mohseni; Ferry Sandra; Keli Song; Brian K Kay; Roya Khosravi-Far
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

7.  Remote Limb Preconditioning Generates a Neuroprotective Effect by Modulating the Extrinsic Apoptotic Pathway and TRAIL-Receptors Expression.

Authors:  Wei Xu; Wei Jin; Xiaoxiao Zhang; Jing Chen; Chuancheng Ren
Journal:  Cell Mol Neurobiol       Date:  2016-03-14       Impact factor: 5.046

8.  Macrophage migration inhibitory factor governs endothelial cell sensitivity to LPS-induced apoptosis.

Authors:  Rachel L Damico; Alan Chesley; Laura Johnston; Eric P Bind; Eric Amaro; Julie Nijmeh; Bedri Karakas; Laura Welsh; David B Pearse; Joe G N Garcia; Michael T Crow
Journal:  Am J Respir Cell Mol Biol       Date:  2008-01-31       Impact factor: 6.914

9.  Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling.

Authors:  V O Kaminskyy; O V Surova; T Piskunova; I B Zborovskaya; E M Tchevkina; L Andera; B Zhivotovsky
Journal:  Cell Death Dis       Date:  2013-03-07       Impact factor: 8.469

10.  Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.

Authors:  S Bouralexis; D M Findlay; G J Atkins; A Labrinidis; S Hay; A Evdokiou
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.